Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  INC Research Holdings Inc    INCR

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Rosen Law Firm Announces Investigation of Securities Claims Against INC Research Holdings, Inc. – INCR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 11:04pm CET

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of purchasers of the securities of INC Research Holdings, Inc. (NASDAQ:INCR) resulting from allegations that INC Research may have issued materially misleading business information to the investing public.

On August 1, 2017, INC Research and inVentiv Health, Inc. (“inVentiv Health”) announced the completion of a merger between the two companies. On November 9, 2017, INC Research reported its first financial results after combining with inVentiv Health. The Company’s combined results were negatively impacted by merger-related expenses, an impairment charge and increased amortization expenses. On this news, shares of INC Research fell $16.35 per share or over 28% from its previous closing price to close at $41.15 per share on November 9, 2017.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by INC Research investors. If you purchased shares of INC Research, please visit the firm’s website at http://www.rosenlegal.com/cases-1236.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.


© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INC RESEARCH HOLDINGS INC
11/17 INC RESEARCH HOLDINGS, INC. (NASDAQ : INCR) Files An 8-K Departure of Directors ..
11/17 INC RESEARCH HOLDINGS, INC. : Change in Directors or Principal Officers, Financi..
11/16 Investigation of INC Research Holdings Announced by Holzer & Holzer
11/16 RESEARCH : Glancy Prongay & Murray LLP Commences Investigation on Behalf of INC ..
11/13 INCR Law Offices of Howard G. Smith Continues Investigation on Behalf of INC ..
11/13 INC RESEARCH HOLDINGS INC : Bronstein, Gewirtz & Grossman, LLC Announces Investi..
11/12 Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possib..
11/10 Rosen Law Firm Announces Investigation of Securities Claims Against INC Resea..
11/10 GLANCY PRONGAY & MURRAY LLP : Continues Investigation on Behalf of INC Research ..
11/10 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of INC Research Ho..
More news
News from SeekingAlpha
11/10 INC Research Holdings 2017 Q3 - Results - Earnings Call Slides
11/09 INC Research's (INCR) CEO Alistair MacDonald on Q3 2017 Results - Earnings Ca..
11/09 Midday Gainers / Losers
11/09 INC Research misses by $0.08, misses on revenue
11/08 Notable earnings before Thursday?s open
Financials ($)
Sales 2017 3 087 M
EBIT 2017 489 M
Net income 2017 117 M
Debt 2017 2 707 M
Yield 2017 -
P/E ratio 2017 26,03
P/E ratio 2018 32,54
EV / Sales 2017 2,15x
EV / Sales 2018 1,99x
Capitalization 3 939 M
Chart INC RESEARCH HOLDINGS INC
Duration : Period :
INC Research Holdings Inc Technical Analysis Chart | INCR | US45329R1095 | 4-Traders
Technical analysis trends INC RESEARCH HOLDINGS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 53,8 $
Spread / Average Target 42%
EPS Revisions
Managers
NameTitle
Alistair Macdonald Chief Executive Officer & Director
Michael A. Bell Executive Chairman & President-Commercial Division
Michael Gibertini Chief Operating Officer
Gregory S. Rush Chief Financial Officer & Executive Vice President
Robert W. Breckon Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INC RESEARCH HOLDINGS INC-28.23%3 939
CELLTRION, INC.--.--%24 558
INCYTE CORPORATION5.19%22 258
IQVIA HOLDINGS INC37.36%22 074
LONZA GROUP59.15%19 560
ALNYLAM PHARMACEUTICALS, INC.240.57%12 538